These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 31494973)
1. Prospective randomized controlled trial comparing treatment efficacy and tolerance of picosecond alexandrite laser with a diffractive lens array and triple combination cream in female asian patients with melasma. Wang YJ; Lin ET; Chen YT; Chiu PC; Lin BS; Chiang HM; Huang YH; Wang KY; Lin HY; Chang TM; Chang CC J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):624-632. PubMed ID: 31494973 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Evaluation of Picosecond Alexandrite Laser with a Diffractive Lens Array for Treatment of Melasma in Asian Patients by VISIA Imaging System. Chen YT; Lin ET; Chang CC; Lin BS; Chiang HM; Huang YH; Lin HY; Wang KY; Chang TM Photobiomodul Photomed Laser Surg; 2019 Sep; 37(9):559-566. PubMed ID: 31411549 [No Abstract] [Full Text] [Related]
3. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma. Basit A; Rahman A; Uddin R J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548 [TBL] [Abstract][Full Text] [Related]
4. Photoaging Reversibility in Asian Patients With Melasma Treated Using Picosecond Lasers With a Diffractive Lens Array: A 1-Year Prospective Observational Cohort Study. Lin ET; Chiang HM; Lin BS; Huang YH; Chang CC Dermatol Surg; 2021 Jan; 47(1):e10-e14. PubMed ID: 32271179 [TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780 [TBL] [Abstract][Full Text] [Related]
6. Topical metformin in the treatment of melasma: A preliminary clinical trial. Banavase Channakeshavaiah R; Andanooru Chandrappa NK J Cosmet Dermatol; 2020 May; 19(5):1161-1164. PubMed ID: 31502392 [TBL] [Abstract][Full Text] [Related]
7. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Jeong SY; Shin JB; Yeo UC; Kim WS; Kim IH Dermatol Surg; 2010 Jun; 36(6):909-18. PubMed ID: 20384749 [TBL] [Abstract][Full Text] [Related]
8. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. Grimes PE; Bhawan J; Guevara IL; Colón LE; Johnson LA; Gottschalk RW; Pandya AG J Am Acad Dermatol; 2010 Jun; 62(6):962-7. PubMed ID: 20398959 [TBL] [Abstract][Full Text] [Related]
9. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. Grimes PE Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882 [TBL] [Abstract][Full Text] [Related]
10. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma. Monheit GD; Dreher F J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908 [TBL] [Abstract][Full Text] [Related]
11. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Draelos Z Dermatol Surg; 2011 Jan; 37(1):126-7. PubMed ID: 21214668 [No Abstract] [Full Text] [Related]
12. Combination of fractional erbium-glass laser and topical therapy in melasma resistant to triple-combination cream. Tourlaki A; Galimberti MG; Pellacani G; Bencini PL J Dermatolog Treat; 2014 Jun; 25(3):218-22. PubMed ID: 22385073 [TBL] [Abstract][Full Text] [Related]
13. A Prospective, Split-Face, Randomized Study Comparing a 755-nm Picosecond Laser With and Without Diffractive Lens Array in the Treatment of Melasma in Asians. Manuskiatti W; Yan C; Tantrapornpong P; Cembrano KAG; Techapichetvanich T; Wanitphakdeedecha R Lasers Surg Med; 2021 Jan; 53(1):95-103. PubMed ID: 32865858 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of picosecond Nd:YAG laser (1,064 nm), picosecond alexandrite laser (755 nm) and 2% hydroquinone cream in the treatment of melasma: A randomized, controlled, assessor-blinded trial. Liang S; Shang S; Zhang W; Tan A; Zhou B; Mei X; Li L Front Med (Lausanne); 2023; 10():1132823. PubMed ID: 37056729 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Gong Z; Lai W; Zhao G; Wang X; Zheng M; Li L; Yang Q; Dang Y; Liu L; Zou Y Clin Drug Investig; 2015 Jun; 35(6):385-95. PubMed ID: 25989732 [TBL] [Abstract][Full Text] [Related]
16. The role of 755-nm alexandrite picosecond laser in melasma management. Pulumati A; Jaalouk D; Algarin YA; Nouri K Arch Dermatol Res; 2023 Dec; 316(1):60. PubMed ID: 38151661 [TBL] [Abstract][Full Text] [Related]
17. A Prospective Split-Face Study of the Picosecond Alexandrite Laser With Specialized Lens Array for Facial Photoaging in Chinese. Ge Y; Guo L; Wu Q; Zhang M; Zeng R; Lin T J Drugs Dermatol; 2016 Nov; 15(11):1390-1396. PubMed ID: 28095552 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial. Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574 [TBL] [Abstract][Full Text] [Related]
19. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study. Rendon M; Cardona LM; Bussear EW; Benitez AL; Colón LE; Johnson LA Cutis; 2008 Nov; 82(5):372-8. PubMed ID: 19090343 [TBL] [Abstract][Full Text] [Related]
20. Community-based trial of a triple-combination agent for the treatment of facial melasma. Grimes P; Kelly AP; Torok H; Willis I Cutis; 2006 Mar; 77(3):177-84. PubMed ID: 16610738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]